Literature DB >> 23898083

15,16-Dihydrotanshinone I-induced apoptosis in human colorectal cancer cells: involvement of ATF3.

Fat-Moon Suk1, Wen-Ju Jou, Ren-Jye Lin, Shyr-Yi Lin, Fang-Yu Tzeng, Yu-Chih Liang.   

Abstract

15,16-Dihydrotanshinone I (DHTS) is a component of the traditional Chinese medicinal plant Salvia miltiorrhiza Bunge. In this study, DHTS at as low as 2.5 μg/ml concentration significantly inhibited proliferation of human benign (SW480) and malignant (SW620) colorectal cancer cells, as shown by 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-diphenytetrazoliumromide (MTT) and flow cytometric analysis. Activating transcription factor (ATF)-3, a basic leucine zipper-type transcription factor, was found to be predominantly up-regulated in DHTS-treated SW480 and SW620 cells. The up-regulation of ATF3 was blocked by a c-JUN N-terminal kinase (JNK) or p38 inhibitor. Overexpression of ATF3 resulted in a significant augmentation of DHTS-induced apoptosis of SW480 cells, but resistance to DHTS-induced apoptosis of SW620 cells. These results suggest that DHTS has a strong therapeutic or preventive potential against cancer. In addition, ATF3 has a dual role in DHTS-induced apoptosis, depending on the degree of malignancy of colorectal cancer.

Entities:  

Keywords:  15,16-Dihydrotanshinone I; SW420 cells; SW480; SW620; activating transcription factor-3; colorectal cancer

Mesh:

Substances:

Year:  2013        PMID: 23898083

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  High-throughput screen of natural product libraries for hsp90 inhibitors.

Authors:  Jason Davenport; Maurie Balch; Lakshmi Galam; Antwan Girgis; Jessica Hall; Brian S J Blagg; Robert L Matts
Journal:  Biology (Basel)       Date:  2014-02-10

2.  15, 16-Dihydrotanshinone I Inhibits Hemangiomas through Inducing Pro-apoptotic and Anti-angiogenic Mechanisms in Vitro and in Vivo.

Authors:  Yihong Cai; Fan Lv; Nurshat Kaldybayeva; Abilova Zhamilya; Zhixiang Wu; Yeming Wu
Journal:  Front Pharmacol       Date:  2018-01-30       Impact factor: 5.810

3.  NDRG1 Downregulates ATF3 and Inhibits Cisplatin-Induced Cytotoxicity in Lung Cancer A549 Cells.

Authors:  Aolin Du; Yufeng Jiang; Chuifeng Fan
Journal:  Int J Med Sci       Date:  2018-10-20       Impact factor: 3.738

4.  Synthetic Fluororutaecarpine Inhibits Inflammatory Stimuli and Activates Endothelial Transient Receptor Potential Vanilloid-Type 1.

Authors:  Chi-Ming Lee; Jiun-An Gu; Tin-Gan Rau; Chi Wang; Chiao-Han Yen; Shih-Hao Huang; Feng-Yen Lin; Chun-Mao Lin; Sheng-Tung Huang
Journal:  Molecules       Date:  2017-04-19       Impact factor: 4.411

5.  15,16-Dihydrotanshinone I from the Functional Food Salvia miltiorrhiza Exhibits Anticancer Activity in Human HL-60 Leukemia Cells: in Vitro and in Vivo Studies.

Authors:  Jun-Jen Liu; Hsueh-Hsia Wu; Tzu-Ho Chen; Wan Leung; Yu-Chih Liang
Journal:  Int J Mol Sci       Date:  2015-08-17       Impact factor: 5.923

6.  Low-cytotoxic synthetic bromorutaecarpine exhibits anti-inflammation and activation of transient receptor potential vanilloid type 1 activities.

Authors:  Chi-Ming Lee; Jiun-An Gu; Tin-Gan Rau; Che-Hsiung Yang; Wei-Chi Yang; Shih-Hao Huang; Feng-Yen Lin; Chun-Mao Lin; Sheng-Tung Huang
Journal:  Biomed Res Int       Date:  2013-11-28       Impact factor: 3.411

7.  Anti-proliferative Effect of 15,16-Dihydrotanshinone I Through Cell Cycle Arrest and the Regulation of AMP-activated Protein Kinase/Akt/mTOR and Mitogen-activated Protein Kinase Signaling Pathway in Human Hepatocellular Carcinoma Cells.

Authors:  Ji-Young Hong; So Hyun Park; Hyen Joo Park; Sang Kook Lee
Journal:  J Cancer Prev       Date:  2018-06-30

8.  Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene.

Authors:  Xiaoqing Wang; Xiao Xu; Guoqiang Jiang; Cuili Zhang; Likun Liu; Jian Kang; Jing Wang; Lawrence Owusu; Liye Zhou; Lin Zhang; Weiling Li
Journal:  J Cell Mol Med       Date:  2020-08-29       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.